Axsome Therapeutics, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Q3 2026 net product revenue was $259.7M (52% YoY growth): AUVELITY $207.6M (+53% YoY), SUNOSI $48.2M (+47% YoY), SYMBRAVO $3.9M (+88% YoY). Net loss improved to $12.9M ($0.25/share) vs. $47.2M loss prior year. Cash balance $313.9M; company states it can fund operations to cash flow positivity. Initiated SUMMIT Phase 3 trial for AXS-05 in smoking cessation; multiple pipeline milestones anticipated through 2027.
Why this rating
Strong commercial execution and approaching cash flow positivity (relative to $4.4B market cap and burn rate) is meaningful. Multiple Phase 3 readouts in 2027 create near-term catalysts but execution risk remains.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.